Evidence map›Paper›PMID 38405804›Full record

ArticlebioRxiv : the preprint server for biology2024

Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.

Daniel J Salas-Escabillas, Megan T Hoffman, Jacee S Moore, Sydney M Brender, Hui-Ju Wen, Simone Benitz, Erick T Davis, Dan Long, Allison M Wombwell, Nina G Steele and 4 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Daniel J Salas-EscabillasCancer Biology, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-0819-989X
Megan T HoffmanDepartment of Immunology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0003-0907-9977
Jacee S MooreDepartment of Surgery, Henry Ford Health, Detroit, MI.ORCID 0009-0007-3853-7769
Sydney M BrenderDepartment of Surgery, Henry Ford Health, Detroit, MI.
Hui-Ju WenDepartment of Surgery, Henry Ford Health, Detroit, MI.
Simone BenitzDepartment of Surgery, Henry Ford Health, Detroit, MI.
Erick T DavisDepartment of Surgery, Henry Ford Health, Detroit, MI.
Dan LongDepartment of Surgery, Henry Ford Health, Detroit, MI.
Allison M WombwellDepartment of Surgery, Henry Ford Health, Detroit, MI.
Nina G SteeleDepartment of Surgery, Henry Ford Health, Detroit, MI.ORCID 0000-0003-1564-3562
Rosalie C SearsDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-1558-2413
Ichiro MatsumotoMonell Chemical Senses Center, Philadelphia, PA.
Kathleen E DelGiornoDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN.ORCID 0000-0002-5749-8394
Howard C CrawfordDepartment of Surgery, Henry Ford Health, Detroit, MI.ORCID 0000-0001-9360-3019
Henry Ford Health System · USDana-Farber Cancer Institute · USMonell Chemical Senses Center · USOregon Health & Science University · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6M
Training Program in Tumor MicroenvironmentT32CA009676 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, Analisa Virginia DiFeo · 1992 to 2026
$7.3M
Hydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2M
Fibroblast orchestration of the immune response in pancreatic cancerU01CA274154 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Howard C. Crawford, Timothy Louis Frankel · 2022 to 2026
$4.2M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas CancerU01CA224145 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRAWFORD, HOWARD C., PASCA DI MAGLIANO, MARINA · 2017 to 2021
$2.6M
The Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0M
A multi-modality approach to decode epithelial heterogeneity and function in metaplasiaR35GM142709 · NIGMS · VANDERBILT UNIVERSITY · PI DELGIORNO, KATHLEEN ELIZABETH · 2021 to 2025
$2.0M
Investigating Cellular Communication in the Tumor Microenvironment in Pancreatic CancerR00CA263154 · NCI · HENRY FORD HEALTH SYSTEM · PI STEELE, NINA G · 2022 to 2024
$862k
Investigating Cellular Communication in the Tumor Microenvironment in Pancreatic CancerK99CA263154 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STEELE, NINA G · 2021 to 2021
$135k
NCI NIH HHS F31 CA271576NCI NIH HHS K99 CA263154NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA236733NCI NIH HHS R00 CA263154NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NCI NIH HHS T32 CA009676NCI NIH HHS U01 CA224012NCI NIH HHS U01 CA224145NCI NIH HHS U01 CA274154NIDDK NIH HHS P30 DK058404NIGMS NIH HHS R35 GM142709
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) is partly initiated through the transdifferentiation of acinar cells to metaplastic ducts that act as precursors of neoplasia and cancer. Tuft cells are solitary chemosensory cells not found in the normal pancreas but arise in metaplasia and neoplasia, diminishing as neoplastic lesions progress to carcinoma. Metaplastic tuft cells (mTCs) function to suppress tumor progression through communication with the tumor microenvironment, but their fate during progression is unknown. To determine the fate of mTCs during PDA progression, we have created a lineage tracing model that uses a tamoxifen-inducible tuft-cell specific Pou2f3

Identifiers

PMID38405804
PMCPMC10888969
OpenAlexW4391885068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.